Purchase Order HHSN261201700258P

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $16,085.00 on May 17, 2019, with ultimate completion on June 14, 2020. Performance occurs in Bethesda, Maryland. The order is a firm fixed price service agreement with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute issued a $3,598.76 delivery order to Illumina, Inc. on January 24, 2018, for materials for project, with final completion scheduled for February 18, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $12,875.00 on July 25, 2018, with an ultimate completion date of July 31, 2019. No set-aside was used. Work is performed at Bethesda, Maryland. The order is priced on a firm fixed price basis and procures sequencing instruments, reagents, consumables, or bioinformatics software aligned with Illumina's product portfolio in support of cancer research operations.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>

<p>The National Cancer Institute issued a $5,100.20 delivery order to Illumina, Inc. on August 24, 2017, with an ultimate completion date of September 25, 2017.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not specify the parent vehicle or the specific goods or services being delivered under this order.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 10, 2017, with a ceiling value of $4,973.52.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed price with an ultimate completion date of August 10, 2017. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $4,066.13 on December 4, 2017, with a completion date of January 31, 2018. The order covers a maintenance agreement for Illumina sequencing equipment. Work is performed in San Diego, California. The purchase order carries firm fixed price terms and no set-aside designation.</p>